InMode (INMD) Q4 2025: International Revenue Jumps 38% as U.S. Market Stabilizes
International growth offset U.S. softness for InMode in Q4 2025, with Europe delivering record revenue and consumables pointing to early stabilization in patient activity. The company’s pivot to lasers and expanded product mix is expected to pressure margins in 2026, but management signals a stabilization year as sector headwinds persist. Strategic alternatives and capital allocation reviews add a layer of uncertainty for investors watching for a potential inflection in demand or corporate structure.
Summary
- Europe Drives Resilience: International sales surged, balancing ongoing U.S. demand softness.
- Product Mix Shift: New laser launches and consumables growth signal evolving business model.
- Margin Pressure Ahead: Lower-margin lasers and tariffs weigh on 2026 outlook despite early signs of recovery.
Business Overview
InMode develops, manufactures, and markets minimally and non-invasive medical aesthetic devices for procedures such as body contouring, skin rejuvenation, and women’s health. The company earns revenue through system sales, consumables, and services. Its major segments include minimally invasive platforms (like Morpheus8, radiofrequency-based treatments), non-invasive products (including new lasers), and recurring consumables tied to procedure volume.
Performance Analysis
InMode’s Q4 2025 results reflect a business in transition, with international operations—especially Europe—delivering record revenue and offsetting ongoing U.S. softness. International sales accounted for 47% of Q4 revenue, growing 38% year-over-year, while total company revenue declined 6% for the full year. Consumables and service revenue, which signal procedure volume and patient activity, rose to 22% of full-year sales, up from 20% in 2024, hinting at stabilization in the installed base.
Margins compressed as the product portfolio shifted toward lasers and as tariffs took effect, with non-GAAP operating margin dropping to 26% for 2025 from 33% the prior year. Sales and marketing expenses remained elevated due to increased investment in commercial teams and new product launches, while average selling prices in North America declined 9%, reflecting competitive dynamics and pricing pressure. The company returned $127.4 million to shareholders via buybacks, signaling confidence in its capital position.
- International Expansion Outpaces Domestic: Europe and other regions now make up nearly half of sales, providing a buffer against U.S. cyclicality.
- Consumables Uptick Indicates Usage Stabilization: Slight growth in procedure-linked consumables suggests underlying patient demand is steadying.
- Margin Compression Driven by Lasers and Tariffs: New laser products and import costs are set to weigh further on gross margins in 2026.
Overall, InMode is leaning on its global footprint and product innovation to weather a slow U.S. recovery, but faces a year of stabilization rather than growth as it absorbs margin headwinds and competitive shifts.
Executive Commentary
"While total revenue decline approximately 6% year over year, revenue from consumable and services increased slightly compared to last year. We believe this may represent early signs of stabilization in patient activity and usage level across our install base."
Moshe Mizrachi, CEO
"The decrease [in margin] was primarily attributable to higher sales and marketing expenses... [and] lasers tend to have a lower gross margin, as everyone in the industry knows very, very well. And we expect those two new lasers that we launched in 2026 to weigh in on our gross margins a little bit."
Yair Malka, CFO
Strategic Positioning
1. International Diversification as a Revenue Anchor
Europe and other international markets are now nearly half of InMode’s revenue mix, with direct subsidiaries driving growth in new geographies such as Austria, Belgium, Argentina, and Thailand. The company’s strategy is to deepen direct sales in large markets and supplement with distributors in smaller ones, increasing control and margin where possible.
2. Product Mix Evolution and Margin Trade-Offs
InMode is expanding its portfolio with new laser devices, including CO2 and PicoLaser platforms, sourced from external partners to address the “bread and butter” of the aesthetics market. While this broadens the addressable market and offers cross-platform synergies, it comes at the cost of lower gross margins and increased exposure to tariffs, especially for imported devices.
3. Commercial Realignment and Sales Force Segmentation
The company unified its North American operations and segmented its sales force by product line, aiming to drive productivity and specialization (e.g., a dedicated team for Envision). This realignment is expected to yield tangible results in 2026, with a focus on both aesthetic and wellness categories.
4. R&D and Clinical Expansion
Investment in R&D will increase in 2026, driven by two large clinical studies in women’s health and ongoing work for new device indications (such as dry eye). Management sees these as essential for long-term differentiation and regulatory expansion, even as near-term returns are uncertain.
5. Strategic Alternatives and Capital Allocation
The board is actively reviewing strategic alternatives, including buybacks and other options with Bank of America advising. This follows substantial share repurchases and reflects a focus on unlocking shareholder value amid perceived undervaluation.
Key Considerations
InMode’s quarter was defined by international momentum, evolving product strategy, and a cautious approach to margin management. The company is navigating a complex landscape of industry headwinds, margin trade-offs, and strategic reviews.
Key Considerations:
- European Outperformance as a Buffer: Record international sales are mitigating U.S. market weakness, but sustainability depends on continued regional execution.
- Laser Portfolio Brings Margin Dilution: New externally sourced lasers expand TAM but carry lower gross margins and add import cost risk.
- Sales Force and Operational Realignment: Unified North American structure and product-focused teams are intended to drive efficiency and market share recovery.
- Strategic Review Uncertainty: Ongoing evaluation of alternatives, including M&A or further buybacks, introduces potential for structural change or capital deployment shifts.
- R&D and Regulatory Pathways: Increased investment in clinical studies and new indications could yield future growth but will pressure near-term operating spend.
Risks
InMode faces persistent U.S. demand softness, competitive pricing pressure, and gross margin dilution from its shift into lasers and exposure to tariffs on imports. The ongoing strategic review adds uncertainty around capital allocation and corporate direction. Regulatory timelines for new indications are extended, and the company’s stabilization outlook signals limited near-term growth, leaving it vulnerable if macro or competitive conditions worsen.
Forward Outlook
For Q1 2026, InMode guided to:
- Revenue between $365 million and $375 million for full-year 2026
- Non-GAAP gross margin between 75% and 77%
- Non-GAAP operating income between $87 million and $92 million
- Non-GAAP EPS between $1.43 and $1.48
Management emphasized a stabilization year, with:
- Laser product launches expected to lower margins but expand market reach
- Early signs of procedure and consumables stabilization, particularly in Europe
Takeaways
Investors should focus on InMode’s ability to sustain international momentum, manage margin trade-offs, and execute on product and sales force realignment while the U.S. market stabilizes.
- International Growth Offsets U.S. Weakness: Europe’s record quarter and global expansion are key to steadying overall performance as U.S. demand remains subdued.
- Margin Pressures to Persist: The shift to lasers and tariff exposure will keep gross margins below historical levels even as new products drive incremental sales.
- Strategic Review Outcome is a Wildcard: Ongoing board evaluation of alternatives, including further buybacks or M&A, could reshape the company’s trajectory in 2026.
Conclusion
InMode enters 2026 positioned as a global leader in minimally and non-invasive aesthetics, but faces a year of stabilization marked by margin headwinds, evolving product strategy, and strategic review uncertainty. Execution in international markets and disciplined capital deployment will be critical for value realization as the U.S. market slowly recovers.
Industry Read-Through
InMode’s results highlight the importance of international diversification and product mix adaptation for medical aesthetics companies facing U.S. demand headwinds. Margin compression from laser adoption and tariff pressures is likely to affect peers entering similar categories. The ongoing strategic review reflects broader industry trends of consolidation, capital allocation scrutiny, and the need for operational agility in a slow-growth environment. Companies with global reach and the ability to innovate across modalities are best positioned to weather industry softness and capitalize on eventual demand recovery.